In order to promote pharmaceutical research and development, a cooperation agreement has been signed with the Semmelweis University (SE) and Pfizer Gyógyszerkereskedelmi Kft. – the signatory parties informed MTI.
According to the announcement, the cooperation in the field of clinical research will increase the research and development capacity of Semmelweis University and contribute to the increase in the number of clinical drug trials.
Péter Vereckei, a Pfizer The managing director of Gyógyszerkereskedelmi Kft. Said: Hungary is consistently among the top ten countries in terms of the number of clinical trials launched among the countries where Pfizer operates.
Between 2014 and 2018, the company spent HUF 16.4 billion on clinical research in Hungary, and in 2019 HUF 1.239 billion was spent on the research services of Hungarian professionals and institutions in their research aimed at developing new therapeutic procedures and drugs.
Béla Merkely, Rector of Semmelweis University, spoke about the proof of the university’s professionalism and international recognition that the institution has become one of the best research institutes in the world conducting clinical trials.
– .
